octocenter-logo

Progression of Early Onset Alzheimer's Disease

Progression of Early Onset Alzheimer's Disease

Factors Affecting Progression

Age of Onset

The age at which symptoms begin to manifest, known as the age of onset, is a critical factor impacting disease progression. While this age can significantly differ among individuals, it typically appears from the 40s to the 60s. However, a few instances have exhibited onset as early as the 20s or 30s. Typically, those displaying signs at an earlier age encounter a quicker cognitive deterioration and disease progression. Even though age of onset holds significant impact, it doesn't clinch the progression rate, as variations across individuals persist.

Genetics

Genetics hold considerable weight in dictating the progression of Alzheimer's disease in its early stages. Certain genetic defects have been linked to an incline in condition risk. For instance, the mutation of the APP gene on chromosome 21 leads to an overabundance of amyloid-beta protein, a defining trait of this disease. The PSEN1 gene mutation, which aids the breakdown of amyloid-beta, also contributes to the excessive amyloid-beta build-up. The APOE gene, particularly the APOE ε4 allele, is known to heighten the risk of reaching early-stage Alzheimer's disease. These genetic anomalies not only influence the age of symptom manifestation but also manipulate the severity and lengthened progression of Alzheimer's disease. This enforces the significance of understanding genetics in early stage Alzheimer's progression.

progression of early onset alzheimers disease

Overall Health

One's overall health status has a prominent part to play in the progression of early-stage Alzheimer's. Vital lifestyle choices like a balanced diet, regular physical exertion, and sufficient sleep might potentially decelerate Alzheimer's progression. Handling chronic ailments such as diabetes, hypertension and heart disease is crucial, given their capacity to escalate cognitive dysfunction. Regular health examinations play a crucial role in early detection and treatment of any underlying issues and in the management of the disease. Lifestyle modifications like smoking cessation and minimal alcohol consumption can also make a powerful, positive impact on Alzheimer's progression. Therefore, prioritizing health could potentially boost overall wellness and possibly decelerate the forward march of the disease.

Early Symptoms and Stages

Mild Cognitive Impairment (MCI)

The stage of Mild Cognitive Impairment (MCI) often preludes the development of Alzheimer's disease, featuring cognitive decline that is unusually obvious for a person's age, yet not severe enough to significantly disrupt daily activities. Observable signs might encompass memory lapses, difficulty expressing thoughts verbally, dwindling levels of focus, and issues with problem-solving. The progression from MCI to mild Alzheimer's disease is not a given for everyone, with some remaining stable or even showing improvement. Consistent assessment and monitoring are crucial for detecting changes in cognitive abilities and administering adequate interventions and support.

Mild Alzheimer's Disease

In the Mild Alzheimer's Disease stage, individuals experience a conspicuous decrease in cognitive function, including lapses in memory, confusion, and increasing difficulties in logical reasoning and decision-making. They might face a tough time articulating their thoughts, frequently misplace things, and struggle with tasks that were previously familiar to them. Mood and personality alterations marked by a heightened irritability or withdrawal may also be noticeable. While those with mild Alzheimer's Disease can independently carry out routine tasks, assistance for more intricate activities might be required, along with added supervision for their safety. The progression of Mild Alzheimer's Disease can vary widely between individuals, complicating the prediction of the declining cognitive function timeline with any certainty.

Moderate Alzheimer's Disease

By the stage of Moderate Alzheimer's Disease, symptoms have significantly worsened, increasingly impacting daily functioning. Memory loss intensifies at this stage, along with a further deterioration of communication abilities culminating in confusion about time and place, alongside continuing struggles with reasoning and decision-making. Unpredictable behavioural shifts may occur**, with increased restlessness, aggression, and a tendency to wander.** Trouble with motor skills and coordination may begin to surface, complicating even basic tasks like dressing and grooming. Individuals at this stage often necessitate more intensive personal assistance and monitoring to ensure safety. A supportive and structured environment is key, fostering engagement in meaningful activities and addressing any arising medical or psychiatric issues.

Bibliography

  1. Gomez, W., Morales, R., Maracaja-Coutinho, V., Parra, V., & Nassif, M. (2020). Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. Aging (Albany NY), 12(1), 1011. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977673/)

  2. Mumford, P., Tosh, J., Anderle, S., Wikberg, E. G., Lau, G., Noy, S., ... & Wiseman, F. K. (2022). Genetic mapping of APP and amyloid-β biology modulation by trisomy 21. Journal of Neuroscience, 42(33), 6453-6468. (https://www.jneurosci.org/content/jneuro/42/33/6453.full.pdf)

  3. Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021). Early-onset Alzheimer's disease: what is missing in research?. Current neurology and neuroscience reports, 21, 1-10. (https://link.springer.com/article/10.1007/s11910-020-01090-y)

  4. Reitz, C., Rogaeva, E., & Beecham, G. W. (2020). Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference?. Neurology Genetics. (https://ng.neurology.org/content/6/5/e512)

  5. Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., ... & Grinberg, L. T. (2021). Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain, 144(7), 2186-2198. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502474/)

  6. Pike, K. E., Cavuoto, M. G., Li, L., Wright, B. J., & Kinsella, G. J. (2022). Subjective cognitive decline: level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies. Neuropsychology review, 32(4), 703-735. (https://research-repository.griffith.edu.au/bitstream/handle/10072/413735/Pike1484212-Accepted.pdf?sequence=2)

  7. Yang, Y., Xiao, M., Leng, L., Jiang, S., Feng, L., Pan, G., ... & Huang, P. (2023). A systematic review and meta‐analysis of the prevalence and correlation of mild cognitive impairment in sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 14(1), 45-56. (https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcsm.13143)

  8. Cao, Y., Liu, P., Bian, H., Jin, S., Liu, J., Yu, N., ... & Ma, C. (2023). Reduced neurogenesis in human hippocampus with Alzheimer's disease. Brain Pathology, e13225. (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bpa.13225)

  9. Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021). Soluble amyloid-β consumption in Alzheimer's disease. Journal of Alzheimer's Disease, 82(4), 1403-1415. (https://content.iospress.com/articles/journal-of-alzheimers-disease/jad210415)

  10. Wiels, W. A., Wittens, M. M., Zeeuws, D., Baeken, C., & Engelborghs, S. (2021). Neuropsychiatric symptoms in mild cognitive impairment and dementia due to AD: relation with disease stage and cognitive deficits. Frontiers in psychiatry, 12, 707580. (https://www.frontiersin.org/articles/10.3389/fpsyt.2021.707580/full)